2 unknown, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Cellect Biotechnology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients ApoGraft - Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant | Phase 1 | Terminated | Washington University School of Medicine | 4 | 2020-12-16 | 2023-05-19 |
| Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study non intervational - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Unknown | Cellect Biotechnology | 12 | 2018-06-10 | 2019-11-26 | |
| Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation Allogeneic MPBC transplantation from matched related donor - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Cellect Biotechnology | 12 | 2017-01-01 | 2019-11-26 |
Autoimmune Lymphoproliferative Syndrome, Type IB (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Israel (2) · United States (1)
Mark Schroeder, M.D. (1) · Tsila Zuckerman, MD (1)